Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

Diabetologia

Volumn 59, Issue 4, 2016, Pages 700-708

  Muscelli, Elza ^a   Astiarraga, Brenno ^a   Barsotti, Elisabetta ^a   Mari, Andrea ^b   Schliess, Freimut ^c   Nosek, Leszek ^c   Heise, Tim ^c   Broedl, Uli C ^d   Woerle, Hans Juergen ^d   Ferrannini, Ele ^a,e  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

^c Profil   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Empagliflozin; Endogenous glucose production; Glycosuria; Metformin; Type 2 diabetes

Indexed keywords

CARBOHYDRATE; EMPAGLIFLOZIN; FAT; GLUCAGON; GLUCOSE; INSULIN; METFORMIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ARTICLE; CALORIMETRY; DRUG EFFECT; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PREMEDICATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; AGED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2;

AGED; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED;

EID: 84959467737     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3845-8     Document Type: Article

References (34)

1. Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733–794
2. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM (2011) Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300:C14–C21
3. Vallon V, Platt KA, Cunard R et al (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104–112
4. Boehringer Ingelheim International GmbH (2015). Jardiance (empagliflozin). Summary of product characteristics. Available from www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002677/WC500168592.pdf. Accessed 27 Apr 2015
5. AstraZeneca AB (2015). Forxiga (dapagliflozin). Summary of product characteristics. Available from www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf. Accessed 27 Apr 2015
6. Janssen-Cilag International NV (2015). Invokana (canagliflozin). Summary of product characteristics. Available from www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf. Accessed 27 Apr 2015
7. Poole RM, Dungo RT (2014) Ipragliflozin: first global approval. Drugs 74:611–617
8. Poole RM, Prossler JE (2014) Tofogliflozin: first global approval. Drugs 74:939–944
9. Markham A, Elkinson S (2014) Luseogliflozin: first global approval. Drugs 74:945–950
10. Zambrowicz B, Freiman J, Brown PM et al (2012) LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 92:158–169
11. Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM (2015) Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab 17:591–598
12. Sykes AP, Kemp GL, Dobbins R et al (2015) Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab 17:98–101
13. Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8:495–502
14. Liakos A, Karagiannis T, Athanasiadou E et al (2014) Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 16:984–993
15. Liakos A, Karagiannis T, Bekiari E, Boura P, Tsapas A (2015) Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 6:61–67
16. Plosker G (2014) Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 74:807–824
17. Rosenstock J, Seman LJ, Jelaska A et al (2013) Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 15:1154–1160
18. Ferrannini E, Berk A, Hantel S et al (2013) Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36:4015–4021
19. Häring HU, Merker L, Seewaldt-Becker E et al (2014) Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37:1650–1659
20. Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose co-transporter-2 inhibition in type 2 diabetic patients. J Clin Invest 124:499–508
21. Merovci A, Solis-Herrera C, Daniele G et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509–514
22. Mutel E, Gautier-Stein A, Abdul-Wahed A et al (2011) Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon. Diabetes 60:3121–3131
23. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:429–442
24. Ferrannini E (2014) The target of metformin in type 2 diabetes. N Engl J Med 371:1547–1548
25. Gastaldelli A, Casolaro A, Pettiti M et al (2007) Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clin Pharmacol Ther 81:205–212
26. Watson PE, Watson ID, Batt RD (1980) Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 33:27–39
27. Mari A, Stojanovska L, Proietto J, Thorburn AW (2003) A circulatory model for calculating non-steady-state glucose fluxes. Validation and comparison with compartmental models. Comput Methods Prog Biomed 71:269–281
28. Ferrannini E (1988) The theoretical bases of indirect calorimetry: a review. Metabolism 37:287–301
29. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of β-cell action: modelling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166
30. Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377
31. Wu T, Thazhath SS, Bound MJ, Jones KL, Horowitz M, Rayner CK (2014) Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? Diabetes Res Clin Pract 106:e3–e6
32. Cuthbertson J, Patterson S, O’Harte FP, Bell PM (2011) Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism 60:52–56
33. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E (2015) Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition. Diabetes Care 38:1730–1735
34. Peters AL, Buschur EO, Buse JB et al (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:1687–1693